International activities | European Medicines Agency (EMA)
WEBEMA's international cooperation activities aim to: ensure the quality of medicines and the integrity and security of the supply chain; ensure the integrity of data used to support clinical trials and manufacturing; encourage a global approach to authorisation and supervision of …
European Medicines Agency (EMA)
WEBFeatured news and updated for European Academics and researchers in the field of medicine development. The European Medicines Agency is a decentralised agency of the European Union responsible for the evaluation, supervision and safety monitoring of …
International cooperation on pharmaceuticals - European …
WEBThe European Commission (DG SANTE) and the European Medicines Agency (EMA) work together to forge close ties with partner organisations around the world, in close cooperation with EU countries. These activities encourage the timely exchange of regulatory and scientific expertise and information, and the development of best practices in the ...
The European Medicines Agency's EU conditional marketing authorisations ...
WEBJan 30, 2021 · Few medicines are awaited as eagerly as COVID-19 vaccines. Extraordinary efforts by scientists, regulators, and developers enabled the European Medicines Agency (EMA) to recommend the first EU conditional marketing authorisation (CMA) for the BioNTech COVID-19 mRNA vaccine (nucleoside-modified) BNT162b2 (Comirnaty) 1 some 9 months after the ...
WEBTo help building a true European Health Union, the strategy aims to the tackle long-standing weaknesses in the area of medicines, weaknesses that have been further exacerbated and thrown into sharp focus by the current COVID-19 pandemic.
WEBIntroduction. Methodology and the Country & Therapy Area KPIs. IQVIA’s 5 Observations in 2022. Q&A. 9 therapy classes with biosimilar competition are shown. The products are split into 4 categories based on regulatory and protection status. Therapy classes. Human Growth Hormone (HGH) Granulocyte-colony Stimulating Factor (GCSFs) Epoetin (EPO)
The Biosimilar Landscape: An Overview of Regulatory Approvals by …
WEBThe regulatory approval pathway for biosimilar medicines at EU level was first developed in 2005, enabling the European Medicines Agency (EMEA, currently EMA) to approve the first biosimilar, Omnitrope, in 2006 .
WEBThe Commission, the European Medicines Agency (EMA), the medicines regulatory authorities in the Member States and the European Economic Area work together in the European medicines regulatory network to ensure that patients have access to high-quality, effective and safe medicines.
Darzalex - opinion on variation to marketing authorisation | European …
WEB3 days ago · On 19 September 2024, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending a change to the terms of the marketing authorisation for the medicinal product Darzalex. The marketing authorisation holder for this medicinal product is Janssen-Cilag International N.V. The CHMP adopted a new indication as follows: Darzalex is indicated: in combination with ...
Competition in pharmaceuticals: more product- than price …
WEBOct 9, 2017 · In general, the intrinsic limit of ‘market failure’ in health care [2] has steered a simplistic approach to competition in the pharmaceutical literature, mainly focused on price competition after patent expiry and with scant attention to product competition earlier.
Skip to content